Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.

Emicizumab(ACE 910) is a bispecific monoclonal antibody that bridges activated factor IX and activated factor X to mimic the function of activated factor VIII. Emicizumab is used for the prevention and treatment of hemophilia A.

Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, and triggers T-cell killing when the CEA on the surface of the cancer cells ranges from intermediate to high levels.Cibisatamab may be used to study solid cancers such as colorectal cancer.

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC).

Denecimig (Mim8) is a bispecific and humanized IgG4κ antibody mimicking activated coagulation factor VIII with anti-FIXa and anti-FX arms, which is used for the treatment of hemophilia A and coagulation disorders primarily by facilitating the assembly of activated coagulation factors IXa (FIXa) and X (FX) on platelet membranes, stimulating activation of FX, and arresting bleeding.

Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.

Talquetamab (JNJ-64407564) is a GPRC5D bispecific antibody for multiple myeloma (MM) that induces T-cell-mediated killing of GPRC5-expressing MM cells through T-cell recruitment and activation, demonstrating antitumor activity.

Blinatumomab (AMG-10,MT-103) is a CD19/CD3 bispecific B-cell and T-cell binding antibody that directs T-cells to attack cancer cells by binding to both CD3 on T-cells and CD19 on cancer cells, and is used in acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Catumaxomab （LP-000） is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM (Epithelial Cell Adhesion Molecule) for the treatment of malignant ascites in cancer patients.

Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors.

Vanucizumab is a bispecific humanised monoclonal antibody that simultaneously inhibits the receptor interactions of VEGF-A and Angiopoietin-2 (Ang-2), exhibiting anti-angiogenic and anti-cancer effects, and can be used for the treatment of advanced solid tumours.

Fidasimtamab is a recombinant human IgG1 bispecific antibody designed to target and inhibit both HER2 and PD-1 signaling pathways. Fidasimtamab bridges PD-1 expressing T cells with HER2 expressing tumor cells, thereby modulating immune responses while exhibiting potential immunosuppressive and antitumor effects. This mechanism provides an unique therapeutic approach for cancer research.

Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.

Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.

RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

Rezetamig is a monoclonal antibody targeting CD3E and CD22.

Xirestomig is a monoclonal antibody that targets TNFRSF9/CD274.

MS133 is a human bispecific antibody targeting CD133/PROM1 and CD3E. It is used in the study of colon cancer.

COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.

SAR442257 is a humanized IgG4-S228P (κ type) monoclonal antibody designed to target CD38 on the surface of multiple myeloma cells, while also co-stimulating CD3 and CD28 molecules on T cells.

RO7122290 is a bispecific antibody-like fusion protein composed of a trimeric ligand for the T-cell co-stimulatory receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulatory and antitumor activities. It shows promise in the treatment of advanced solid tumors. Molecular weight: 177.78 KD.

Hb0025 is a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts antitumor effects by inhibiting VEGF activity and facilitating T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. Molecular weight: 170.8 KD.